LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Other Non-current Assets
Long-term assets not reported separately.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets remains negative
Q1 FY2026 other non-current assets was $0, compared with $508K a year earlier.
Context
- Other non-current assets amounted to 0.0% of total assets at the end of Q1 FY2026, down 2.6 pp from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 498K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Non-current Assets vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 other non-current assets of $0 is the lowest of the 10 companies compared; the peer median is $2.46M.
- Its year-over-year change of -100.0% is the lowest of 8, against a peer median of +47.3%.
- Other non-current assets amounts to 0.0% of total assets for LBRX, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $487.03M | — | — | 0.5% | |
| Sep 2026 | $77.65M | -2.8% | +147.6% | 4.3% | |
| Jun 2026 | $25.83M | +12.4% | +29.7% | 2.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $2.61M | +126.6% | +37.6% | 0.2% |
| Mar 2026 | $2.46M | +125.2% | — | 0.9% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $1.06M | +400.9% | — | 0.2% |
| Mar 2026 | $838K | +47.3% | +83.2% | 0.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $53K | — | -76.6% | 0.0% |
| Mar 2026 | $36K | -98.9% | -36.8% | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $0 | -100.0% | — | 0.0% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $2.46M | +47.3% | +33.6% | 0.3% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.